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Abstract: In the last two decades, new insights have been gained regarding sex/gender-related
differences in cardiovascular disease (CVD). CVD represents the leading cause of death worldwide
in both men and women, accounting for at least one-third of all deaths in women and half of
deaths in women over 50 years in developing countries. Important sex-related differences in
prevalence, presentation, management, and outcomes of different CVDs have been recently discovered,
demonstrating sex/gender-specific pathophysiologic features in the presentation and prognosis of
CVD in men and women. A large amount of evidence has highlighted the role of sex hormones in
protecting women from CVDs, providing an advantage over men that is lost when women reach
the menopause stage. This hormonal-dependent shift of sex-related CVD risk consequently affects
the overall CVD epidemiology, particularly in light of the increasing trend of population aging. The
benefits of physical activity have been recognized for a long time as a powerful preventive approach
for both CVD prevention and aging-related morbidity control. Exercise training is indeed a potent
physiological stimulus, which reduces primary and secondary cardiovascular events. However,
the underlying mechanisms of these positive effects, including from a sex/gender perspective, still
need to be fully elucidated. The aim of this work is to provide a review of the evidence linking
sex/gender-related differences in CVD, including sex/gender-specific molecular mediators, to explore
whether sex- and gender-tailored physical activity may be used as an effective tool to prevent CVD
and improve clinical outcomes in women.
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1. Introduction
Sex/gender-related differences in cardiovascular disease (CVD) risk, clinical phenotype, and
outcome have been discovered in the past two decades [1]. These new concepts have an important
translational value as CVD is the leading cause of death in older people and there is a global increase in
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the elderly population. Notably, almost 60% of elderly patients with atherosclerotic CVD have either
no conventional risk factors or just one [2].
Of particular relevance is the issue of heart failure, which is expected to double each decade of life
and to grow significantly in the whole population due to the dramatic increasing trend of population
aging, particularly in the developed countries [3]. Although several novel molecular markers and
pharmacogenetic studies have been used to intensively investigate complex polygenic chronic or
degenerative diseases [4–13] leading to the discovery of novel prognostic biomarkers or inherited
predispositions [14–19], specific dedicated therapies to treat heart failure due to heart wall remodeling
do not currently exist, and women experience the worst prognosis [1,20,21]. Epidemiological data
highlight that CVD now represents the leading cause of mortality and hospital admission for women,
accounting for one in three deaths worldwide and half of all deaths of women over 50 in developing
countries [3]. By contrast, breast cancer, considered in the past to be the leading cause of death in
women, now accounts for just 3% of all deaths in the female adult population [1,22]. Several studies
and reports have unequivocally demonstrated the key role of sex hormones in protecting women from
CVD during the premenopausal state, providing an advantage over men that is lost when the hormonal
profile changes at menopause transition. This hormonal-dependent shift of sex-related CVD risk
strongly affects CVD epidemiology and CVD prevention/treatment, particularly in light of the aging of
the overall population [20,23]. These clinical data suggest that novel risk factors that are still not well
established may contribute to the development of CVD in a sex- and gender-dependent fashion.
In real practice, new therapeutic treatments useful to men have not led to a significant decrease in
CVD fatality rates in women [1,24], supporting the key role of sex/gender differences in determining
CVD risk, diagnosis, and prognosis and explaining the existing gap in the progress achieved to treat
CVD in women compared to men [25]. The emerging view is that disparities in knowledge regarding
CVD in women over men can be overcome through a sex/gender-based “holistic” approach to disease
pathophysiology [1,20], spanning from clinical signs and manifestations up to risk establishment,
diagnosis definition, and dedicated treatment design through appropriate clinical trials in which the
role of sex and gender differences can be properly evaluated in terms of therapeutic response [22]. In
fact, although milestone studies in the last few decades have allowed the development/optimization of
actual standard care in the context of CVD by taking advantage of more accurate clinical tests that have
allowed a better definition of the risks and benefits of effective prevention/therapies, the majority of
these studies did not appropriately consider women. Thus, much of the actual standard care available
to test, prevent, and treat CVD in women can be considered a mere translation of the findings of studies
conducted predominantly on middle-aged men [3], an approach that is inappropriate and risky given
the emerging role of sex/gender differences in CVD pathophysiology. To apply the findings of studies
on male cohorts to females for the management of CVD may be inappropriate for several reasons,
including dissimilarities in symptoms of CVD, natural disease history, and response to therapies that
are different in men and women [26]. A proper consideration of sex/gender-related differences in
medicine and particularly in the evaluation of occurrence, risk evaluation, presentation, therapy, and
outcomes of CVD is a recent achievement [3]. It is now widely recognized that there is an incremental
shift in how CVD should be treated in women. This has left healthcare professionals unprepared,
mainly because of the poor understanding of sex/gender-specific differences in the pathophysiology of
CVD, resulting in a dramatic absence/insufficiency of diagnostic and therapeutic guidelines to address
personalized differences in women [1,3].
A paradigmatic example of sex differences in CVD is the clinical manifestation and symptom
presentation, with women more likely to show ischemia with no obstructive coronary arteries (INOCA),
although they report more chest pain compared to men [27–30]. However, sex differences may
also have a different impact on traditional CVD risk factors. Diabetes is associated with higher
ischemic heart disease (IHD) in women compared to men, even if risk factors are exclusive to women
(e.g., pregnancy-related complications) or they mainly disadvantage women (e.g., depression) [30].
In addition, comorbidities, such as psychological factors, vasoconstriction, and microcirculatory
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dysfunction during mental stress, are phenomena highly prevalent in patients with angina and more
pronounced in women [31].
The current view clearly suggests a multifactorial model, with sex hormones playing a crucial role
by interacting with traditional and nontraditional risk factors, in turn affecting atherosclerotic plaque
deposition and/or vascular/metabolic pathways and resulting in poorer outcomes in women [32].
Furthermore, although the major CV risk factors are the same in both sexes, sex/gender-specific biases
have been recognized [33], and these differences are related to different outcomes. Data from the
Framingham Heart Study by Kannel and co-workers demonstrate that the clinical manifestation of
atherosclerotic CVD is extremely rare in younger women compared to men of similar age. The analysis
of CVD incidence suggests that premenopausal women have fewer CV and coronary events compared
to men as well as postmenopausal women of the same age, even if there is also substantial sex-related
variability in the prevalence/outcome associated with traditional cardiac risk factors, such as family
history of premature coronary heart disease (CHD), cholesterol levels, hypertension, smoking, or
obesity [34,35].
Studies aimed at precision medicine are providing increasing data highlighting that it is indeed
no longer possible to avoid a proper consideration of sex/gender differences when approaching disease
pathophysiology [36–38]. Environmental, social, and psychological differences can contribute to
sex/gender imbalances in CVD. In the same fashion, sex hormones account for emerging sex-related
differences in CVD, as elucidated by recent investigations of molecular mechanisms [39,40]. Newly
identified risk indicators, including inflammatory markers such as high-sensitivity C-reactive protein,
IL-6, fibrinogen, and acute phase protein as well as other pathophysiological processes such as retinal
artery narrowing, coronary artery calcification, endothelial dysfunction, and anemia, are now being
studied in women [41]. Finally, the gut microbiome, harboring trillions of microbial cells, is gaining
increasing interest as it has been demonstrated to play an important role in the development of
CAD [42,43]. In this context, Li and colleagues recently reported that plasma levels of trimethylamine
N-oxide, a metabolite derived from precursors of diet originating from gut microbiota activity, was
a prognostic biomarker of major adverse cardiovascular event (MACE) risk in short- and long-term
follow-up [44]. Moreover, the growing interest in the role of microbiome in disease pathophysiology
has led to the discovery of microbiome-related sex differences that have been suggested to be
involved in pathological contexts, such as inflammation, autoimmunity, cardiometabolic diseases, and
depression [45,46]. Sex differences in microbiome belong to different causes, including (but not limited
to) different genetic background, diverse energy balance, and dietary needs across the lifespan as well
as differences in gastrointestinal transit time [47].
Differences between men and women in terms of effects of physical exercise have been
reported, and sex/gender-specific studies are gaining increasing attention and highlighting crucial
implications in several health issues, including cardiac adaptation to exercise as well as CVD
prevention/rehabilitation [48–54].
In this scenario, the aim of the present review is to critically discuss key evidence related to
sex/gender-related differences in CVD and examine the beneficial role of physical activity to support
a potential role of sex/gender-tailored physical exercise to target CVD physiopathological processes
and improve clinical outcomes, particularly in women, by highlighting the key molecular and cellular
mediators involved.
2. Women-Specific CVD Risk Factors and Their Molecular Mechanism
CVD has long been considered a male-specific disease even though CVD also affects women,
although later in life than in men. There is also a misperception that CVD among women is not as
severe as it is in men [55], despite evidence of a progressive increase in CVD in women as demonstrated
by epidemiological data.
In 2016, Garcia and colleagues extensively studied the unique aspects of CV health in women [56]
and provided an in-depth analysis of sex and gender differences relating to clinical practice in the
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prevention, diagnosis, and treatment of CVD. One of the main differences in the prevalence of CVD in
women, particularly in postmenopausal women, is certainly the effect of estrogen in the regulation of
vascular endothelium and the cardiovascular system. According to Sciomer and co-workers, sex/gender
disparities in cardiology also stem from biological differences, including endothelial cell dysfunction
processes [23]. The role of nitric oxide (NO) in physiological endothelial cell biology/homeostasis
as well as in the pathophysiological processes underlying atherosclerosis and vascular disease has
been widely investigated, as reviewed in [57]. In terms of sex-related differences in CVD, it is of great
relevance that estrogen also modulates endothelial functions by increasing the expression and activity
of endothelial NO synthase (eNOS) by genomic and nongenomic mechanisms [58]. In particular,
by interacting with estrogen receptor-α (ERα), estrogen modulates endothelial and vascular smooth
muscle cell functions via the mitogen-activated protein kinase (MAPK) pathway [39]. In this context,
the estrogen decline characterizing menopause (as well as the presence of alterations in ERα) is coupled
with impaired NO-mediated effects, including reduced endothelial healing/angiogenesis/vasodilatation
and altered inflammatory status [59].
Together with changes in the hormonal profile, the higher risk and occurrence of CVD experienced
by postmenopausal woman can also be related to additional (perhaps synergic) causes, including
differences in response to emotional/physical stress and/or sex- and gender-specific vascular and
metabolic effects [42,60,61]. In the same fashion, the complex cascade mediated by estrogen may lead
to changes in coagulation and other systems, accounting for the key role of sex hormone fluctuations
in establishing CVD risk, including those occurring during menopause and pregnancy [39,62]. A
recent study by Baetta and co-workers [37] clearly reviewed the current status of studies investigating
the molecular basis of sex differences in CVD, mainly through the proteomic approach. In this
regard, studies on the circulating levels of potential soluble CVD markers have revealed sex-specific
differences, such as those in serum levels of the adipocyte fatty acid-binding protein (A-FABP),
emerging as a relevant atherosclerosis marker in women (i.e., with different fat distribution and
hormonal regulation compared to men), supporting the need for sex/gender-specific biomarkers to
be translated in clinical practice [63,64]. Accordingly, it has been recently demonstrated that females
with angina are more thrombogenic than males, and this inevitably affects clinical outcome and
prognosis [65]. Important sex differences have been identified in fat distribution, with women typically
showing peripheral subcutaneous adipose tissue, while men tend to accumulate more central adipose
and visceral adipose tissue [26]. These various findings may have a great role in establishing sex- and
gender-related differences in CAD risk because low endothelial shear stress promotes the development
of atherosclerosis [66] and it has been associated with fat accumulation/distribution, endothelial wall
remodeling, inflammation, and plaque instability [67,68].
Particularly with regard to endothelium modifications and their relationship to CVD, in 1994,
Celermajer and colleagues [69] published data from 103 men and 135 women with no risk factors
for atherosclerosis. The results indicated that artery flow-mediated dilatation (FMD)—an index of
endothelial functionality response to increased luminal shear stress, at least in the NO-mediated
part [70] that predicts cardiovascular events [71–73]—declined in men at an earlier age than in
women. The authors also noted a steep decline of artery FMD in women that coincided with the
time of menopause [69]. In 1995, Hashimoto and colleagues [74] were the first to evaluate vascular
endothelium changes during the menstrual cycle. They highlighted that FMD was equal to that of
males at low circulating estradiol levels, while FDM responses were increased in the presence of
high estradiol (i.e., follicular phase) [74]. These data have been confirmed by several independent
laboratories, including the recent report by Williams and co-workers [75]. A number of different studies
have recently investigated the molecular mechanisms associated with the impacts of 17β-estradiol on
vascular functions and endothelium remodeling, suggesting that these adaptations, which include
the generation of NO and prostacyclin, possibly act through the promotion of endothelial repair and
regeneration via the production of anti-inflammatory and antioxidant agents depending on the receptor
subtype [76,77].
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The role of estrogen receptors is indeed crucial in the atherosclerotic process where, in addition to
the classical estrogen receptors (i.e., ERα and estrogen receptor-β (ERβ) shown to mediate opposite
effects), other receptors may be involved, suggesting that the balance between the different ERs
may be responsible for the different responses and effects [23,78]. Moreover, a very recent study
on an adult zebrafish model demonstrated that the heart strongly responded to 17β-estradiol in a
sex-specific manner, suggesting that zebrafish could be used as a model to identify novel sex-targeted
cardiovascular therapies [79]. Finally, a recent study by Tarhouni and co-workers [80] demonstrated an
essential role of 17β-estradiol and ERα in flow-mediated remodeling of resistance arteries, suggesting
potential synergic impacts of endothelial shear stress and estrogen signaling in terms of vascular
adaptation following exercise and training in vivo. Notably, vascular stiffness is a recognized CVD
risk factor with sex-specific differences and mechanisms, showing a superior role in postmenopausal
women affected by CVD (e.g., preferential heart failure with preserved ejection fraction or isolated
systolic hypertension) [81].
3. Impact of Exercise Training on CVD Risk
Exercise training is recognized as a powerful stimulus that is able to control and decrease
primary [82,83] and secondary cardiovascular events [84]. However, as reported by the World Health
Organization (WHO), about 23.4% of adult males and 31.7% of adult females (aged over 18 years)
are not active enough (2016 data). The crisis is even more severe when considering the fact that 81%
of adolescents aged 11–17 years are not active enough and young girls (88.4%) are significantly less
active compared to their age-matched young male counterparts (82.4%). Furthermore, stratifying by
regions, women are generally less active than men (with the exception of the Western Pacific region),
and young adolescent girls are at a higher risk of developing noncommunicable diseases (e.g., heart
disease, stroke, cancer, diabetes, and chronic lung disease) and death (Figure 1) [85].
Figure 1. Prevalence of insufficient physical activity as reported by WHO (https://www.who.int/gho/
ncd/risk_factors/physical_activity/en/; data from 2016) in adults (aged 18+ years) and adolescents
(11–17 years) stratified by sex and region.
An excessively high level of physical inactivity was also reported in the Eurobarometer on Sport
and Physical Activity of the EU in March 2018 [86]. Insufficient physical activity increases the risk
of CVD, heart disease, cancer, stroke, and diabetes by 20%–30% and shortens the lifespan by 3–5
years [85]. Exercise improves artery and muscle functions [87] and seems to be of great importance in
the prevention/modulation of a number of atherogenic processes [88]. Therefore, it is likely that due
to improvements in vascular functions, exercise and physical activity could be linked to reduction
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in CVD [89]. In particular, considering that the worse CVD prognosis in females is partly due to the
nonoptimized therapies they receive as described above, an improvement in time/quality of physical
exercise could be a way to bridge this gap between the sexes. The fact that males have historically been
more likely to be involved in specific sports/physical activities that are different from those practiced
by females must also be taken into account (Figure 2).
Figure 2. Comparison of common sports engaged in according to sex in the US (data from the American
Time Use Survey, https://www.bls.gov/spotlight/2008/sports/; The Bureau of Labor Statistics (BLS)).
Tinker and co-workers [83] were the first to investigate the protective effects of vascular remodeling
during exercise in healthy subjects. They demonstrated that an increase in FMD following an acute
bout of handgrip exercise was dependent on increased shear stress and that functional and remodeling
vascular adaptations to training were therefore dependent on shear stress. Moreover, they defined
exercise training as providing a potent physiological stimulus to adaptation in endothelial function
and vascular remodeling, noting that this particular shear stress in response to exercise training in
healthy humans is the principal mechanism responsible for exercise-induced vascular adaptations in
function and structure [83].
Many studies have reported significant inverse association of physical activity with mortality and
CVD morbidity [61]. In particular, in a systematic review and meta-analysis, Lin and colleagues clearly
indicated that exercise training improved cardiorespiratory fitness and cardiometabolic biomarkers
belonging to different biological pathways, such as lipid/lipoprotein metabolism, glucose intolerance,
insulin resistance, and systemic hemostasis/inflammation, thereby highlighting sex as one of the
variables that may differentiate the effects and benefits of exercise at the CV level together with
age and health status [90]. Other advantages have also been reported, including positive effects on
mitochondrial function, re-establishment of vasculature, release of myokines from the skeletal muscle
that preserve or augment cardiovascular functions [91], and mitochondrial selective autophagy in the
view of the crucial role of mitochondria in maintaining cardiac homeostasis (Figure 3) [92].
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Figure 3. Schematic representation of the most relevant mechanisms mediating cardiovascular (CV)
responses/improvements due to physical exercise, which may help to establish differences between
the sexes.
It is worth noting that different consideration and attention should be paid to different types of
physical activities. In particular, leisure/recreational activities and occupational-related activities (e.g.,
housework, transportation, lifting heavy loads) should be distinguished, with the latter being less
proven (up to now) by epidemiological studies in terms of disease prevention/risk establishment [93].
In a recent study published in the Lancet, Lear and colleagues [94] recruited 168,916 participants
from 17 countries, 141,945 of whom completed the study, to investigate whether different levels
and types of physical activity are associated with different outcomes in terms of mortality and CVD
in countries at different socioeconomic levels [94]. During follow-up, there were 5334 total deaths,
including 1294 from CVD causes and 4040 deaths from non-CVD causes. Results suggested that
high physical activity was associated with lower CV risk for all outcomes independent of the type of
physical activity (i.e., recreational or nonrecreational). In addition, the association between any type
of physical activity and a lower CVD risk (e.g., mortality and major events) was independent of the
presence of other risk factors [94].
In addition to physical/CV effects, the positive benefits of physical exercise have also been
recognized at the emotional, social, and psychological levels. However, the fact that people of
different sex/gender may need different types/requirements (e.g., intensity and duration) of physical
exercise is rarely considered. In fact, while there is a general agreement on the benefits obtained
by both sexes when moving from sedentary to moderate physical activity [95], reports in the field
appear to suggest that more intense physical exercises may lead to different outcomes in men and
women [96–98]. In particular, the impact of a shift from moderate to strong/energetic physical training
appears to mainly favor men, while women seem to gain benefits from low to moderate exercise with
no additional positive outcomes when increasing the intensity, particularly among postmenopausal
women [99]. With regard to cardiovascular health outcomes, low/moderate physical activities have
been reported to be more protective in women in terms of CVD risk, coronary heart disease, and
other pathological conditions, such as diabetes [49,97,100–104]. However, few studies have so far
compared the response to different types of exercise in women and men in the prevention of CVD risk
and during rehabilitation [49,105–109]. It is of interest that recent studies on the effects induced by
endurance and endurance–strength exercise in women characterized by obesity revealed that not only
were there exercise-mediated improvements in terms of renal function [110], liver function [111], and
mineral homeostasis [112] but that the type of exercise could make a difference in terms of biochemical
parameter markers of exercise-mediated benefits [111].
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In terms of mechanistic insights, these sex-related differences may be obviously attributed to
anatomical/biological cardiovascular differences between men and women, such as heart rate during
physical exercise, size and number of red cells, and airway and lung development, just to cite few
paradigmatic parameters that may significantly affect the response and performance to a specific type
of physical training. Similarly, sex-specific differences, also linked to natural intrinsic differences and
sex-specific thresholds, have been reported with regard to benefits from both aerobic exercise and
resistance training, with women showing a lowering of diastolic pressure following resistance training
while men showed benefits in terms of increase in arterial stiffness, suggesting the need for sex-specific
exercise as intervention [113].
Sex-related differences have also been investigated at the preclinical level in animal models to
evaluate the role of sex hormones and other molecular mediators, such as NO and myosin heavy chain
expression, on the regulation mediated by physical activity [114,115]. Interestingly, a recent study
by Rosenfeld [116] investigated sex-related differences in physical activity levels in both rodents and
humans, highlighting the brain regions and the signaling pathways that are most likely involved.
Overall, preclinical and human subject studies support the evidence of sexually dimorphic differences
in physical activity. More specifically, animal studies suggest that, under basal conditions, females
tend to be more active than males [117], whereas human males are more active than females [118,119].
It is of interest that human males tend to have more intrinsic motivators linked/leading to physical
activity, such as the need/desire to improve health quality, prevent disease onset, and improve body
shape as well as being competitive. On the contrary, females of different ages appear to be motivated
to undertake physical exercise by different stimuli, such as emotional involvement, socialization, and
mental and physical wellbeing as well as the achievement and maintenance of a positive self-image.
In this scenario, within the different genes and pathways identified in the brain and shown to be
involved in the stimulation or suppression of these behavioral responses, a role has been hypothesized
for Fos/DeltaFosB [120] and leptin signaling pathways [121]. In particular, it has been shown that
dopamine-mediated neuronal activities in the CNS of females are dependent on estrogens and ER
distribution in different brain regions [122,123]. A sex-dependent estrogen mediation of dopamine
signaling pathways has been highlighted in females in the striatum and nucleus accumbens, which is
linked to reproductive success overall [116].
4. Conclusions
CVD is the leading cause of death worldwide and remains a major global economic burden. Recent
findings have highlighted the existence of crucial sex/gender-related differences in the prevalence,
presentation, management, and outcomes of different CVDs, which are related to differences in fat
tissue distribution and different hormonal profiles and fluctuations, such as those during the menstrual
cycle, pregnancy, and delivery in women. Moreover, evidence and findings of studies have recently
assessed the importance of exercise and physical activity in the reduction of CVD, strongly suggesting
the need for physical exercise-based medicine along with a personalized-medicine approach.
We are aware that there are major limitations involved, particularly relating to the absence of
well-established protocols to investigate and measure the biological effects of different physical exercise
training in the context of CVD, along with the lack/scarcity of preclinical/clinical studies properly
addressing the role of gender, other than the one of sex. Nonetheless, we believe that the focus of the
present review in addressing a potential sex/gender-specific approach to preventing/managing CVD
in women, which is at a disadvantage in the long term due to the clinical standard care, is of great
relevance and may be of inspiration for new and innovative research in the field [1,3,8].
Further studies are indeed needed to define if an increase in physical activity/training in women
should be defined at appropriate levels, in different intensities, and according to the type of exercise
in order to maximize the positive effects on health, CVD prevention, and rehabilitation processes.
Similarly, gender-specific aspects should also be taken into account at different ages to identify
habits, attitudes, and behaviors that may influence the outcomes of physical exercise. Differences in
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gender-related imprinting during the early phases of life may indeed become more relevant during
adult life, accounting for educational, social, and cultural rules that may influence behaviors, lifestyle,
adherence to training schedules, and transgenerational epigenetic inheritance (Figure 4).
Figure 4. Snapshot of key differences in sex/gender features to be considered in physical activity to
improve cardiovascular health, decrease cardiovascular disease (CVD) risk, and settle personalized
training/rehabilitative exercise protocols.
Finally, particular attention should be paid in the future to the transgender population. In light of
the use of sex hormone treatments, this population will need careful consideration in order to address
the real impact of therapies on metabolic profile, CVD risk, and other pathological conditions such as
diabetes as well as to establish how tailored physical activity may decrease disease risk.
In conclusion, a better understanding of the genetic and molecular mechanisms driving
sex/gender-related differences is needed in order to promote mechanism-based precision medicine
protocols and gain insights for the development of sex-specific therapeutic strategies for CVD based
on ad-hoc and ad personam physical exercise approaches.
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Abbreviations
CAD coronary artery disease
CV cardiovascular
CVD cardiovascular disease
ERα estrogen receptor-α
ERβ estrogen receptor-β
ERs estrogen receptors
eNOS endothelial nitric oxide synthase
FMD flow-mediated dilatation
a-FABP adipocyte fatty acid-binding protein
IHD ischemic heart disease
MACE major adverse cardiac event
MAPK mitogen-activated protein kinase
NO nitric oxide
WHO World Health organization
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